Males or females of reproductive potential may not participate unless they have agreed to use an effective double barrier contraceptive method for the entire duration of protocol therapy and for 3 months (males) and 1 month (females) after study drug discontinuation
Males and females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
Patients must not be pregnant or nursing; women and men of reproductive potential must have agreed to use an effective contraceptive method
Males or females of reproductive potential may not participate unless they have agreed to use two effective contraceptive methods; abstinence in a non-sexually active child will be sufficient birth control
Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during the time they are receiving the study drug and for 3 months thereafter; abstinence is an acceptable method of birth control; oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study; women of childbearing potential will be given a pregnancy test within 7 days prior to administration of RAD001 and must have a negative urine or serum pregnancy test; pregnancy tests should be repeated every course +/- 4 days
Patients must not be pregnant or nursing; women/men of reproductive potential must agree to use an effective contraceptive method during and for 6 months after completing protocol treatment; a negative pregnancy test is required within 7 days prior to registration for women of child-bearing potential
Pregnant or breast-feeding females are excluded; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method; abstinence is an acceptable method of birth control
Patients must not be pregnant or nursing because of the potentially harmful effects of these agents on a developing fetus; women/men of reproductive potential must have agreed to use an effective contraceptive method
Pregnant or nursing patients due to risk of fetal or nursing infant harm. Women/men of reproductive potential who do not agree to use an effective contraceptive method while on study and for at least 6 months after study treatment
Pregnant or breast-feeding patients; men and women of reproductive potential may not participate in this study unless they have agreed to use an effective contraceptive method while in this study
Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during the period they are receiving the study drug and for 3 months thereafter; abstinence is an acceptable method of birth control; women of childbearing potential will be given a pregnancy test within 7 days prior to administration of cabozantinib and must have a negative urine or serum pregnancy test
Men and women of reproductive potential may not participate unless they agree to use an effective contraceptive method
Pregnant or breast-feeding females are excluded; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method; abstinence is an acceptable method of birth control
Females of child-bearing potential must have a negative pregnancy test within 14 days prior to registration; patients with reproductive potential must agree to use an effective contraceptive method during treatment
Pregnant or nursing women may not participate; women of childbearing potential may not participate unless they have agreed to use an adequate contraceptive method throughout study treatment and for one month after completion of treatment
Men of reproductive potential may not participate unless they agree that they will use an effective contraceptive method such as condom/diaphragm, spermicidal foam, etc - until six months after the end of all radiation therapy
Pregnant or breast-feeding patients; men and women of reproductive potential may not participate in this study unless they have agreed to use an effective contraceptive method while in this study; (postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential); patients must agree to continue contraception for 3 months from the date of the last study drug administration
Women/men of reproductive potential unwilling or unable to use an effective contraceptive method
Pregnant or nursing women; men or women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
Patients of reproductive potential must agree to use an effective contraceptive method during participation in this trial and for 6 months after the trial
Patients of reproductive potential must agree to use an effective contraceptive method during participation in this trial and for 6 months after the trial; patients must not be breastfeeding
Patients must not be pregnant or nursing. Women/men of reproductive potential must have agreed to use an effective contraceptive method (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
Pregnant or nursing women are ineligible and patients of reproductive potential must agree to use an effective contraceptive method during participation in this trial
Non-pregnant and non-nursing; men and women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on the study
Women/men of childbearing potential must have agreed to use a highly effective contraceptive method during and for 6 months after completion of chemotherapy.
Patients with reproductive potential declining to use an effective contraceptive method during treatment are excluded from this study.
Pregnant or nursing women; men or women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
Patients at reproductive potential must agree to practice an effective contraceptive method. Women of childbearing potential must not be pregnant or lactating
Patients who are pregnant or nursing; if patients are of reproductive age and have not undergone hysterectomy, they must use an effective contraceptive method for the duration of this study
Women of reproductive potential must have a negative pregnancy test within 14 days prior to registration; patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method
Males and females of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method
Females of reproductive potential must not be pregnant or lactating; males or females of  reproductive potential may not participate unless they have agreed to use an effective contraceptive method
Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method
Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during the period they are receiving the study drug and for 3 months thereafter; abstinence is an acceptable method of birth control; women of childbearing potential will be given a pregnancy test within 7 days prior to administration of PD-0325901 and must have a negative urine or serum pregnancy test
Patient at reproductive potential must agree to practice an effective contraceptive method.
Women of reproductive potential must have a negative blood pregnancy test and agree to use highly effective contraceptive methods.
Pregnant or nursing women may not participate; women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method; pregnancy test required for women of childbearing potential
Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method from the time of study entry to a period of no less than four months post the HSV1716 injection
Pregnant or nursing females; any patient of reproductive potential may not participate unless he/she has agreed to use an effective contraceptive method as covered during the informed consent process
Patients with reproductive potential must use contraceptive methods
Female patients who are post-menarchal must have a negative pregnancy test; patients of reproductive potential must agree to use an effective contraceptive method
Use of an effective contraceptive, as specified by protocol; women of childbearing potential cannot be pregnant or breastfeeding
Pregnant or lactating women may not participate; women/men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
Women who are pregnant or breastfeeding are excluded; patients with reproductive potential must agree to use an effective contraceptive method during treatment
Pregnant, breastfeeding, or women of childbearing potential unwilling to use a reliable contraceptive method
Pregnant or nursing women will not participate; women of reproductive potential must be offered a pre-treatment pregnancy test and informed of the need to practice an effective contraceptive method during the therapy